James (Jim) Robinson is the vice chair of the Coalition for Epidemic Preparedness Innovations (CEPI).
James Robinson | |
|---|---|
| Scientific career | |
| Institutions | G.D. Searle, LLC Sanofi Pasteur Novavax Merck Coalition for Epidemic Preparedness Innovations (CEPI) |
Robinson manages the CEPI manufacturing strategy for a COVID-19 vaccine.[1]
Career
editRobinson began his career as a biochemical engineer with G.D. Searle and worked at various companies before becoming the head of technical support for Merck's vaccine, biologics and sterile manufacturing in 2010.[2][3]
In 2017, Robinson began serving on CEPI's scientific advisory board. He was made vice-chair in 2019.[3]
On February 16, 2022, Robinson was awarded a two-year, $340,000 grant by the Arnold Ventures Foundation to study biosimilars to determine potential cost savings from wider use of them.[4]
References
edit- ^ Heath, Elizabeth Weise and David (26 April 2020). "'Our moon shot': The world needs a coronavirus vaccine ASAP. Despite drugmakers billion-dollar bets, one might not be available for years". USA TODAY. Retrieved 2020-05-20.
- ^ Dumiak, Michael (2017). "A Crisis Gives You WIngs". Iavi Report: Newsletter on International Aids Vaccine Research. 21 (1): 4–9. PMID 29901872. Retrieved 2020-05-20.
- ^ a b Wright, Rob (27 March 2020). "The Little-Known Coalition Tasked With Saving The World From COVID-19". Life Science Leader. Retrieved 2020-05-20.
- ^ MacNeil, Matt (2022-02-16). "James Robinson receives grant to study biosimilars". UC Berkeley Public Health. Retrieved 2023-04-06.